- Home
- PHGE
as 12-20-2024 4:00pm EST
BiomX Inc is a clinical-stage microbiome company based in Israel. The company is engaged in developing both natural and engineered phage cocktails designed to target and destroy harmful bacteria that affect the appearance of the skin, as well as harmful bacteria in chronic diseases, such as inflammatory bowel disease, colorectal cancer, and primary sclerosing cholangitis. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF.
| Founded: | 2015 | Country: | Israel |
| Employees: | N/A | City: | NESS ZIONA |
| Market Cap: | 11.1M | IPO Year: | N/A |
| Target Price: | $22.50 | AVG Volume (30 days): | 72.5K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.69 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.48 - $8.55 | Next Earning Date: | 11-14-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest BiomX Inc. COmmon Stock News
PHGE Breaking Stock News: Dive into PHGE Ticker-Specific Updates for Smart Investing
GlobeNewswire
6 days ago
BiomX Inc. Receives Notice of Compliance with NYSE American Continued Listing Standards
GlobeNewswire
a month ago
BiomX Announces Third Quarter 2024 Financial Results and Provides Business and Program Updates
GlobeNewswire
a month ago
BiomX to Host Third Quarter 2024 Financial Results Conference Call and Webcast on November 14, 2024
TipRanks
2 months ago
BiomX announces mandatory unit separation
GlobeNewswire
2 months ago
BiomX Announces a Mandatory Unit Separation
GlobeNewswire
3 months ago
BiomX to Provide Latest Update on Positive Phase 1b/2a Clinical Trial Data for BX004 at the North American Cystic Fibrosis Conference
GlobeNewswire
4 months ago
BiomX to Present at the H.C. Wainwright 26th Annual Global Investment Conference
GlobeNewswire
4 months ago
BiomX to Present Positive Phase 1b/2a Clinical Trial Data for BX004 at the European Respiratory Society (ERS) Congress 2024
Compare PHGE vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "PHGE BiomX Inc. COmmon Stock - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.